IP Library › Assignment 076084/0283
Patent Assignment
Reel/Frame 076084/0283

Patent Security Agreement

Recorded: 2026-07-30 Pages: 14
Assignor
AUTOLUS LIMITED
Executed: 2026-07-30
Assignee
PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NEW YORK, 10003
Covered Properties (103)
Transcription System
Application: 16/470,965 →
Publication: US US20200095590A1
Compositions and Methods Comprising Engineered Chimeric Antigen Receptor and Modulator of Car
Application: 17/436,673 →
Publication: US US20220145325A1
CAR T-Cell to Activate the Cellular-Mediated Immune Response through Recognition of Peptide/MHC Complexes
Application: 17/601,684 →
Publication: US US20220211830A1
Chimeric Cytokine Receptor Comprising a Truncated Cytokine Receptor Domain
Application: 17/628,509 →
Publication: US US20220289820A1
Trbc Beta Antibody Conjugate
Application: 17/913,649 →
Publication: US US20230109275A1
Cell
Application: 17/915,637 →
Publication: US US20230113183A1
Method for Selecting Cells Expressing a Nucleic Acid of Interest
Application: 17/915,689 →
Publication: US US20230133554A1
Method of Treating Solid Cancer
Application: 17/924,345 →
Publication: US US20230256093A1
Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain
Application: 18/153,990 →
Publication: US US20230220077A1
Cell
Application: 18/158,310 →
Publication: US US20240033289A1
Retroviral And Lentiviral Vectors
Application: 18/160,032 →
Publication: US US20240093232A1
Generation of T-Cells by Direct Reprogramming from Fibroblasts and Msc
Application: 18/279,568 →
Publication: US US20240166996A1
Vectors
Application: 18/504,554 →
Publication: US US20240309400A1
Chimeric Antigen Receptor
Application: 18/515,458 →
Publication: US US20240301088A1
Cell Expressing a Car and a Transcription Factor and Its Use
Application: 18/525,271 →
Publication: US US20240307440A1
Anti-CD307E Single-Domain Antibodies, Uses Thereof in Car T-Cell and for the Treatment of Diseases
Application: 18/570,278 →
Publication: US US20250289891A1
Nucleic Acid Construct
Application: 18/590,698 →
Publication: US US20240384278A1
Chimeric Antigen Receptor
Application: 18/597,357 →
Publication: US US20250019434A1
Chimeric Cytokine Receptor
Application: 18/704,231 →
Publication: US US20260159570A1
T-Cell Receptor Constant Region 1 Antibody or T-Cell Receptor Constant Region 2 Antibody
Application: 18/794,918 →
Publication: US US20250333505A1
CD19/C22 Car T-Cell Treatment of High Risk or Relapsed Pediatric Acute Lymphoblastic Leukemia
Application: 18/862,269 →
Publication: US US20260097122A1
Method
Application: 18/868,402 →
Publication: US US20250345427A1
Cell
Application: 18/954,189 →
Publication: US US20250197464A1
Bcma/CD19 Car for Treating Multiple Myeloma
Application: 18/967,332 →
Publication: US US20250268941A1
Chimeric Antigen Receptor
Application: 18/978,527 →
Publication: US US20250277047A1
Retroviral and Lentiviral Vectors
Application: 18/987,004 →
Publication: US US20250388929A1
Car T-Cells Comprising an Anti CD33, an Anti CLL1 and at Least One Further Car Anti CD123 and/or FTL3
Application: 19/021,501 →
Publication: US US20250381224A1
Chimeric Cytokine Receptor
Application: 19/033,252 →
Publication: US US20250333538A1
Methods
Application: 19/050,681 →
Publication: US US20250314655A1
Compositions and Methods Comprising Engineered Chimeric Antigen Receptor and Modulator of Car
Application: 19/073,904 →
Publication: US US20250296976A1
Chimeric Antigen Receptor
Application: 19/139,245 →
Chimeric Cytokine Receptor, Which Comprises a Truncated IL2RBETA and IL2RGAMMA
Application: 19/166,559 →
Publication: US US20260263519A1
Chimeric Antigen Receptor
Application: 19/172,331 →
Publication: US US20260062458A1
Signalling System
Application: 19/178,505 →
Publication: US US20260085106A1
Cell
Application: 19/281,399 →
Publication: US US20250353893A1
Anti TRBC1 Antigen Binding Domains
Application: 19/412,451 →
Publication: US US20260274948A1
Transcription System
Application: 19/412,507 →
Publication: US US20260193660A1
Cell
Application: 19/459,793 →
Publication: US US20260224627A1
CD19CAR T-Cell Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
Application: 19/487,852 →
Treatment of TRBC1-Positive T Cell Malignancies
Application: 19/491,316 →
Publication: US US20260263599A1
Method
Application: 19/498,920 →
Chimeric Antigen Receptors Directed Against TRBC1 and TRBC2
Application: 19/500,132 →
Anti-TCRB1 and Anti-TCRB2 T Cells
Application: 19/501,916 →
Methods and Cell Compositions
Application: 19/508,279 →
Products and Methods for Treating Autoimmune Diseases
Application: 19/528,476 →
Method for Producing Engineered Immune Cells
Application: 19/528,489 →
Chimeric Antigen Receptor (Car) Comprising a CD19-Binding Domain
Application: 19/691,108 →
Publication: US US20260274946A1
Chimeric Antigen Receptor
Application: 15/028,064 →
Publication: US US20160237139A1
Chimeric Antigen Receptor
Application: 15/123,331 →
Publication: US US20170066838A1
Signalling System
Application: 15/506,383 →
Publication: US US20170260269A1
Chimeric Protein
Application: 15/526,097 →
Publication: US US20170354682A1
A T Cell Which Co-Expresses a CD19 Chimeric Antigen Receptor and a CD22 Chimeric Antigen Receptor
Application: 15/529,690 →
Publication: US US20170369550A1
Retroviral and Lentiviral Vectors
Application: 15/554,499 →
Publication: US US20180066280A1
Chimeric Antigen Receptor (CAR) Comprising a CD19-Binding Domain
Application: 15/555,508 →
Publication: US US20180044417A1
Nucleic Acid Construct
Application: 15/568,862 →
Publication: US US20180099994A1
Chimeric T cell
Application: 15/577,378 →
Publication: US US20190023761A1
Chimeric Cytokine Receptors and Encoding Nucleic Acids
Application: 15/753,486 →
Publication: US US20180244797A1
Chimeric Receptor with Ligand Binding Exodomain and Cytokine and T Cell Signalling Endodomains
Application: 15/770,110 →
Publication: US US20180312570A1
Signalling System
Application: 16/076,760 →
Publication: US US20190330299A1
Chimeric Protein
Application: 16/113,098 →
Publication: US US20190015451A1
Chimeric Cytokine Receptors and Encoding Nucleic Acids
Application: 16/113,224 →
Publication: US US20190016820A1
Chimeric Antigen Receptor
Application: 16/162,747 →
Publication: US US20190100571A1
Method of Preparing T Cells with Increased Activity
Application: 16/188,185 →
Publication: US US20190209612A1
Methods of depleting malignant T-cells.
Application: 16/229,684 →
Publication: US US20200200756A1
Chimeric Antigen Receptor
Application: 16/310,121 →
Publication: US US20190177412A1
Retroviral And Lentiviral Vectors
Application: 16/326,131 →
Publication: US US20190177746A1
Chimeric Antigen Receptor (Car) Comprising a CD19-Binding Domain
Application: 16/573,854 →
Publication: US US20200140544A1
Chimeric Protein
Application: 16/598,652 →
Publication: US US20200222461A1
Anti TRBC1 Antigen Binding Domains
Application: 16/620,370 →
Publication: US US20200140549A1
Cell
Application: 16/646,906 →
Publication: US US20200297766A1
Cell
Application: 16/754,673 →
Publication: US US20200255494A1
Car T-Cells Comprising Transcriptional Circuits
Application: 16/759,222 →
Publication: US US20200308600A1
Polypeptide
Application: 16/766,128 →
Publication: US US20200360432A1
Plasmid System
Application: 16/772,216 →
Publication: US US20230242937A1
Cell Comprising a Chimeric Antigen Receptor or a Transgenic T-Cell Receptor and Comprising a Chimeric TNF Receptor
Application: 16/772,260 →
Publication: US US20210095003A1
Methods for Treating Cancer or Modulating T Cells or Nk Cells in a Subject by Administering Cells Comprising Chimeric Transmembrane Proteins
Application: 16/998,756 →
Publication: US US20210040227A1
Methods for Treating Cancer or Modulating T Cells or Nk Cells in a Subject with Cancer by Administering Cells Comprising Chimeric Cytokine Receptors
Application: 16/999,012 →
Publication: US US20210040228A1
Chimeric Antigen Receptor
Application: 17/054,670 →
Publication: US US20210113618A1
A CD79-Specific Chimeric Antigen Receptor
Application: 17/055,387 →
Publication: US US20220273710A1
Retroviral and Lentiviral Vectors
Application: 17/192,561 →
Publication: US US20210348191A1
Chimeric Antigen Receptor
Application: 17/196,670 →
Publication: US US20210403596A1
Nucleic Acid Construct
Application: 17/254,001 →
Publication: US US20220106602A1
Molecular Assessment of Trbc Usage
Application: 17/264,217 →
Publication: US US20220010377A1
Chimeric Antigen Receptor
Application: 17/279,874 →
Publication: US US20220033509A1
T-Cell Receptor Constant Region 1 Antibody or T-Cell Receptor Constant Region 2 Antibody
Application: 17/287,307 →
Publication: US US20210355217A1
Binding Domain
Application: 17/290,188 →
Publication: US US20220041718A1
Anti TRBC1 Antigen Binding Domains
Application: 17/499,687 →
Publication: US US20220098300A1
Cell
Application: 17/525,244 →
Publication: US US20220267404A1
Chimeric Receptor Comprising a Ligand Binding Domain and an Endodomain Comprising a Cytokine Receptor Endodomain and an Intracellular T Cell Signalling Domain
Application: 17/560,022 →
Publication: US US20220275052A1
Virus-Like Particle
Application: 17/626,990 →
Publication: US US20220249566A1
Chimeric Antigen Receptor
Application: 17/723,209 →
Publication: US US20220257659A1
Cytolytic Immune Cell Comprising Bcma- and CD19-Specific Chimeric Antigen Receptors
Application: 17/746,642 →
Publication: US US20220356260A1
Compositions and Methods Comprising Engineered Chimeric Antigen Receptor and Modulator of Car
Application: 17/746,664 →
Publication: US US20220364116A1
Antigen-Binding Domain
Application: 17/784,392 →
Publication: US US20240252534A1
Chimeric Transmembrane Protein Comprising Antibody Dimerization Domains and a Type I Cytokine Receptor Endodomain, Encoding Nucleic Acids Thereof and Methods of Use Thereof
Application: 17/815,110 →
Publication: US US20230133682A1
Anti TRBC1 Antigen Binding Domains
Application: 17/817,271 →
Publication: US US20230053849A1
Engineered Cytolytic Immunecell
Application: 17/823,003 →
Publication: US US20230090553A1
Methods
Application: 17/832,162 →
Publication: US US20230021548A1
Method for Depleting Malignant T-Cells
Application: 17/832,225 →
Publication: US US20230019650A1
Methods
Application: 17/832,341 →
Publication: US US20230026111A1
Method for Depleting Malignant T-Cells
Application: 17/832,371 →
Publication: US US20230018688A1
A Cell Lexpressing Two Chimeric Antigen Receptors (Cars) at the Cell Surface
Application: 18/158,754 →
Publication: US US20230331810A1
Cell
Application: 18/323,090 →
Publication: US US20240075066A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 20, 2019
From: PULÉ, MARTIN; THOMAS, SIMON; CORDOBA, SHAUN
To: AUTOLUS LIMITED
Reel/Frame 049535/0858 →
Assignment of Assignor's Interest Dec 17, 2021
From: PULÉ, MARTIN; PEDDAREDDIGARI, VIJAY; ITIN, CHRISTIAN
To: AUTOLUS LIMITED
Reel/Frame 058416/0201 →
Assignment of Assignor's Interest Jan 4, 2022
From: PULÉ, MARTIN; CORDOBA, SHAUN; THOMAS, SIMON; ONUOHA, SHIMOBI
To: AUTOLUS LIMITED
Reel/Frame 058538/0796 →
Assignment of Assignor's Interest Mar 9, 2022
From: PULÉ, MARTIN; CORDOBA, SHAUN; ONUOHA, SHIMOBI; THOMAS, SIMON
To: AUTOLUS LIMITED
Reel/Frame 059213/0100 →
Assignment of Assignor's Interest Oct 5, 2022
From: MCKENZIE, CALLUM; CORDOBA, SHAUN; PULÉ, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 061319/0856 →
Assignment of Assignor's Interest Oct 5, 2022
From: ONUOHA, SHIMOBI; FERRARI, MATHIEU; AKBAR, ZULAIKHA; BUGHDA, REYISA
To: AUTOLUS LIMITED
Reel/Frame 061320/0220 →
Assignment of Assignor's Interest Oct 5, 2022
From: MCKENZIE, CALLUM; CORDOBA, SHAUN; PULÉ, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 061319/0988 →
Assignment of Assignor's Interest Nov 10, 2022
From: PERUTA, MARCO DELLA; RIGHI, MATTEO; AGLIARDI, GIULIA; PULÉ, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 061715/0001 →
Change of Name May 5, 2023
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 063557/0692 →
Assignment of Assignor's Interest May 5, 2023
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 063551/0098 →
Assignment of Assignor's Interest May 5, 2023
From: PULÉ, MARTIN; KONG, KHAI; CORDOBA, SHAUN
To: UCL BUSINES PLC
Reel/Frame 063550/0909 →
Assignment of Assignor's Interest May 5, 2023
From: PEDDAREDDIGARI, VIJAY; BESWICK, RICHARD; SHORT, JOHN; PULÉ, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 063551/0421 →
Assignment of Assignor's Interest Jun 9, 2023
From: PULE, MARTIN; MEKKAOUI, LEILA; AMROLIA, PERSIS; GHORASHIAN, SARA
To: UCL BUSINESS PLC
Reel/Frame 063912/0169 →
Assignment of Assignor's Interest Jun 9, 2023
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 063912/0341 →
Change of Name Jun 9, 2023
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 063956/0229 →
Assignment of Assignor's Interest Dec 14, 2023
From: PULÉ, MARTIN; SILLIBOURNE, JAMES; CORDOBA, SHAUN
To: AUTOLUS LIMITED
Reel/Frame 065868/0325 →
Assignment of Assignor's Interest Jan 8, 2024
From: KINNA, ALEXANDER; FERRARI, MATHIEU; ONUOHA, SHIMOBI; PULE, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 066046/0641 →
Assignment of Assignor's Interest Jan 8, 2024
From: PULÉ, MARTIN; ANDERSON, JOHN; THOMAS, SIMON
To: UCL BUSINESS PLC
Reel/Frame 066047/0020 →
Assignment of Assignor's Interest Jan 8, 2024
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 066047/0137 →
Assignment of Assignor's Interest Jan 8, 2024
From: PULÉ, MARTIN; BAI, YUCHEN
To: AUTOLUS LIMITED
Reel/Frame 066047/0377 →
Assignment of Assignor's Interest Jan 8, 2024
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 066221/0328 →
Assignment of Assignor's Interest Jan 8, 2024
From: PULÉ, MARTIN; THOMAS, SIMON; CORDOBA, SHAUN; LIM, WEN CHEAN
To: AUTOLUS LIMITED
Reel/Frame 066047/0323 →
Assignment of Assignor's Interest Feb 5, 2024
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 066385/0634 →
Assignment of Assignor's Interest Feb 5, 2024
From: PULE, MARTIN; ANDERSON, JOHN; THOMAS, SIMON
To: UCL BUSINESS PLC
Reel/Frame 066520/0975 →
Change of Name Feb 5, 2024
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 066494/0087 →